You are here:

docetaxel (Taxotere)

Advice

in the absence of a submission from the holder of the marketing authorisation

docetaxel (Taxotere®) in combination with doxorubicin and cyclophosphamide is not recommended for use within NHS Scotland.

Indication under review:  adjuvant treatment of patients with operable node-negative breast cancer.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result SMC cannot recommend its use within NHSScotland.
 

Drug Details

Drug Name: docetaxel (Taxotere)
SMC Drug ID: 659/10
Manufacturer: Sanofi-Aventis
Indication: for the treatment of patients with operable node-negative breast cancer.
BNF Category:
Sub Category: 8.1 Cytotoxic drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 8 November 2010

Back